Characteristics of patients with DM using icosapent ethyl in the real world
Om P. Ganda, MD
The effect of icosapent ethyl on CV events in metabolic syndrome
Michael Miller, MD
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
Carolyn Lam, MD, PhD
Maria Luiza Caramori, MD, PhD
Ana Maria Cebrián-Cuenca, MD, PhD
Pam R. Taub, MD, FACC, FASPC
Amy Groenewegen, MD
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.